Acute Post-cardiac Surgery Renal Failure: Prevention Through Individualized Intensive Hemodynamic Management

  • STATUS
    Recruiting
  • End date
    Dec 1, 2022
  • participants needed
    240
  • sponsor
    Hospital Clinic of Barcelona
Updated on 1 May 2021
renal failure
nephropathy
renal injury
replacement therapy
chronic kidney disease
heart surgery
coronary artery bypass graft

Summary

BACKGROUND: The incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery can reach 35% and between 2 and 5% require kidney replacement therapy during the AKI episode. The development of AKI n this context is independently associated with higher long-term mortality (5-10 years). In addition, there is strong evidence that an episode of AKI in the hospital increases the risk of developing chronic kidney disease in the medium-long term. On the other hand, once AKI has been recovered according to creatinine values, there are no established biomarkers to predict patients at risk of progression to chronic kidney disease, which will allow us to increase nephroprotection and surveillance measures in this group of patients.

STUDY DESIGN: Open-label randomized unicentric prospective study of patients undergoing valvular replacement heart surgery coronary bypass with acute kidney injury (AKI) risk >30% according to the Leicester Cardiosurgery scale. Patients will be randomized 1:1 in two groups: standard hemodynamic management or intensive hemodynamic management based on premorbid mean perfusion pressure (MPP). The interventional period will span from intra-operation until the first 24 hours postoperative. The incidence of AKI will be evaluated according to KDIGO criteria between 48 hours and 7 days after surgery. Patients will be followed for one year. Biomarkers of mitochondrial damage will be analyzed at various points during the follow-up to patients presenting AKI.

INTERVENTIONS
  1. Group 1/Intensive management: Intra-surgical values of 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group 1 based on cardiac index and 25% MPP will be followed for 24 hours.
  2. Group 2/Standard management: MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed.

Biomarkers of mitochondrial damage will be determined in urine in patients in both groups only in patients developing AKI according to KDIGO guidelines between 48h and 7 days.

EXPECTED RESULTS:A 50% reduction in the incidence of AKI in the intervention group compared to the control group is expected. At the same time, markers of mitochondrial damage are expected to be validated in our cohort as biomarkers of AKI progression and to investigate its usefulness as biomarkers of transition to Chronic kidney disease.

Description

BACKGROUND

The incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery can reach 35% and between 2 and 5% require kidney replacement therapy during the AKI episode. The development of AKI n this context is independently associated with higher long-term mortality (5-10 years). In addition, there is strong evidence that an episode of AKI in the hospital increases the risk of developing chronic kidney disease in the medium-long term. That is why the prevention of AKI is essential to reduce the morbidity that these patients suffer in the hospital and out-of-hospital environment. On the other hand, once AKI has been recovered according to creatinine values, there are no established biomarkers to predict patients at risk of progression to chronic kidney disease, which will allow us to increase nephroprotection and surveillance measures in this group of patients.

STUDY DESIGN:

Open-label randomized unicentric prospective study of patients undergoing valvular replacement heart surgery coronary bypass with acute kidney injury (AKI) risk >30% according to the Leicester Cardiosurgery scale. Patients will be randomized 1:1 in two groups: standard hemodynamic management or intensive hemodynamic management based on premorbid mean perfusion pressure (MPP). The interventional period will span from intra-operation until the first 24 hours postoperative. The incidence of AKI will be evaluated according to KDIGO criteria between 48 hours and 7 days after surgery. Patients will be followed for one year. Biomarkers of mitochondrial damage will be analyzed at various points during the follow-up to patients presenting AKI. Intention to treat population will be defined as patients who sign informed consent and undergo planned surgery.

INTERVENTIONS-ANALYSIS:

  1. Group 1/Intensive management: Baseline mean blood pressure (MAP) and central venous pressure (CVP) will be measured to calculate baseline mean perfusion pressure (MPP). Intra-surgical values of 25% basal MAP will be maintained and once in the ICU an algorithm corresponding to group 1 based on cardiac index and 25% MPP will be followed for 24 hours.
  2. Group 2/Standard management: MAP during surgery will be maintained > 60 mmHg according to usual protocol. Once in ICU, during the first 24 hours an algorithm corresponding to group 2 based on cardiac index, MAP and CVP will be followed. Biomarkers of mitochondrial damage will be determined in urine in patients in both groups only in patients developing AKI according to KDIGO guidelines between 48h and 7 days. The following variables will be assessed in both groups: accumulated fluid balance in first 24 hours, ICU /hospitalization length of stay, days with vasoactive support, MAKE (Major Adverse Kidney Events: mortality, need for renal replacement therapy, persistent renal dysfunction) at 30, 90 and 365 days and other AKI episodes at one year. In the patients who develop AKI, urinary markers of mitochondrial injury will also be measured at 30 days.

EXPECTED RESULTS:

A 50% reduction in the incidence of AKI in the intervention group compared to the control group is expected. At the same time, markers of mitochondrial damage are expected to be validated in our cohort as biomarkers of AKI progression and to investigate its usefulness as biomarkers of transition to Chronic kidney disease.

Details
Condition Renal Failure, Kidney Failure (Pediatric), Kidney Failure, Renal Failure, Acute renal failure, Kidney Failure (Pediatric), Kidney Failure, acute kidney injury, acute kidney injuries
Treatment Intensive management
Clinical Study IdentifierNCT04005105
SponsorHospital Clinic of Barcelona
Last Modified on1 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients undergoing elective or urgent heart surgery with extracorporeal circulation at the Hospital Clnic de Barcelona
Valve and/or aortocoronary bypass surgery
Risk of AKI >30% according to the Leicester Cardiosurgery scale

Exclusion Criteria

End-stage kidney disease stage V
Patients with AKI in the 7 days prior to surgery
Interstitial glomerulonephritis or vasculitis
Pregnancy
Kidney transplant
Endocarditis
Patients with mechanical assistance devices (ECMO, LVAD, RVAD, IABP)
Inclusion in another clinical intervention test during the intervention period
Emergence surgery
Patients in need of pressure-directed therapy of cerebral infusion
Constrictive pericarditis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note